Conversations on 
Twitter :
-
"A record for @GSK?": After speedy clinical program for melanoma treatment, GSK submits for regulatory approval
With @RyanMFierce - Tox concerns for Idenix's hep C treatment? Biotech analysts take an in-depth look
- What comes next in biotech translational capital? Interesting post & discussion on venture gap funding
@FierceBiotech: Yesterday's most popular story: Analyst reads last rites after heart failure scuttles Bristol hepatitis C study. Story | Follow @FierceBiotech
@JohnCFierce: Bankers tally torrid pace for biotech M&A as hungry suitors pounce. More | Follow @JohnCFierce
@RyanMFierce: A record for GSK? Asks for FDA approval for targeted melanoma treatment roughly 3 years after hitting the clinic. More | Follow @RyanMFierce
> GEN rounded up the top 25 most highly paid women in biotech, and three of them appear to have CEO in their titles. Heather Bresch, CEO of Mylan ($MYL), topped the list with 2011 compensation of $9.6 million. Item
> Elusys has grabbed a $50.2 million award from Uncle Sam to develop its anthrax treatment. Article
> Furiex Pharmaceuticals ($FURX) has added $30 million to a $10 million loan, striking a debt agreement with Silicon Valley Bank and MidCap Financial. Release
> Xconomy covered San Diego-based drug developers Sophiris Bio's journey to break into the blockbuster market for prostate cancer drugs. Article
> As expected, GlaxoSmithKline ($GSK) has wrapped up its $3.6 billion buyout of U.S. biotech and long-time partner Human Genome Sciences. Item
Pharma News
@FiercePharma: More on "how not to insider trade," with Bristol-Myers exec as exhibit A, from The Wall Street Journal. More | Follow @FiercePharma
> J&J acknowledges what everyone knows, it settled with DoJ. Story
> Johnson & Johnson releases some Doxil for trials. More
> Investors bite on Pfizer's Sandwich site. News
> GSK tries volume, goodwill, over margins in Africa. Article
> Bloomberg: India's Sun sizes up deal with Germany's Stada. Story
@FierceMedDev: Globus scales back its IPO pricing, now trading under GMED. More | Follow @FierceMedDev
@MarkHFierce: Thoratec reported a Q2 loss but is banking on continued sales growth to carry the year. More | Follow @MarkHFierce
@DamianFierce: NEJM: FDA device approval no slower than EU's. More | Follow @DamianFierce
> NEJM: FDA device approval no slower than EU's. Report
> CA hospital accused of testing Stryker tech without patient consent. Article
> FDA whacks Philips unit with Class I ventilator recall. News
And Finally… Taxes hurt U.S. cigarette sales as smokers take alternative smoking measures. Article